| (Values in U.S. Thousands) | Mar, 2023 | Sep, 2022 | Jun, 2022 | Mar, 2022 | Sep, 2021 |
| Sales | 3 | 4 | 4 | 4 | 4 |
| Sales Growth | -25.00% | unch | unch | unch | unch |
| Net Income | -25,060 | -18,246 | -24,706 | -18,776 | -14,352 |
| Net Income Growth | -37.35% | +26.15% | -31.58% | -30.83% | +2.79% |
Bellus Health Inc (BLU.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
BELLUS Health Inc is a clinical-stage biopharmaceutical development company advancing novel therapeutics for conditions with a high unmet medical need, including BLU-5937, a P2X3 antagonist that has the potential to be a best-in-class therapeutic for chronic cough. The company operates in one business segment namely, the development of drug candidates for health solutions.
Fiscal Year End Date: 12/31